Skip to main content
. Author manuscript; available in PMC: 2023 Nov 1.
Published in final edited form as: Anal Chem. 2022 Oct 20;94(43):14925–14930. doi: 10.1021/acs.analchem.2c02389

Figure 3.

Figure 3.

ARFRP1 is downregulated in radioresistant lines of both MDA-MB-231/C5 and MCF7/C6 pairs of breast cancer cells. (A) The MRM traces of a representative peptide (DCLTQACSALTGK, where underlined C represents carbamidomethylated cysteine) from ARFRP1 in MDA-MB-231/C5 and MCF7/C6 pairs of breast cancer cells. The traces of the unlabeled peptide in parental and radioresistant cell lines are shown in red and the spiked-in isotope-labeled peptide are depicted in blue. (B) Western blot for validating the MRM results for ARFRP1 in MDA-MB-231/C5 and MCF7/C6 cells. (C) Quantification results for the relative levels of expression of ARFRP1 protein in the two pairs of cell lines obtained from MRM and Western blot analyses. Error bars represent S.D. (n = 3).